Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,4,5-Trimethoxyamphetamine (TMA) is a synthetic psychedelic and hallucinogenic compound belonging to the amphetamine class. It acts primarily as a serotonergic psychedelic with modest agonist activity at serotonin receptors such as 5-HT2A and 5-HT2C. TMA produces hallucinogenic effects at doses of approximately 100–250 mg with a duration of action lasting about 6–8 hours. It is structurally related to mescaline but is more potent by weight and has a shorter duration of action. TMA has appeared on the illicit drug market and is classified as a Schedule I controlled substance in the United States[1][2][6][8]. There are no approved medical indications or pharmaceutical uses for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,4,5-trimethoxyamphetamine.